Clinical Trial

An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to: 1\. Evaluate the efficacy of piclidenoson to increase renal uptake of 99mTc-labeled DMSA, in comparison to baseline, after 6 months (26 weeks) of treatment as a measure the reabsorption capacity of LMWPs by renal proximal tubules. The secondary objectives of this trial are to: 1. Evaluate changes in urinary excretion of LMWPs and other clinical parameters of renal Fanconi syndrome 2. Evaluate safety of piclidenoson in patients with Lowe syndrome
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-08.
Trial Details
NCT Number NCT07410455
Lead Sponsor Can-Fite BioPharma
Conditions Lowe Syndrome
Enrollment 5 participants
Start Date 2026-06-01
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-18